The Argentina Pharmaceuticals and Healthcare Report Provides Independent Forecasts and Competitive Intelligence on Argentina’s Pharmaceuticals and Healthcare Industry

by Dave

Possibilities exist for acquiring Argentine pharma companies outright and using that as a base to serve the huge Brazilian market. Where multinationals fear to tread, Indian pharma companies with their cost, scale advantage can do well. Import of finished drugs into Argentina is banned. Active pharma ingredients can be imported.

via Business Wire
Continued infusions of cash by the Brazilian government into public healthcare, and broader positive growth dynamics in Latin America – along with relative weakness in the peso – were the main drivers of exports for Argentine producers. Another reason for looking abroad are the continued persistence of price controls on medicines in Argentina – a major deterrent for multinationals – and more cheeringly, some signs of a harder line being taken by medicines regulator ANMAT.

Back in December, we upgraded the country’s Business Environment Rating (BER) for the Approvals Process subcategory from 4 to 6. Our reappraisal was triggered by the announcement that Argentina will become the first Latin American member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, along with broader improvements seen in enforcing rules on controversial drugs. In January 2008, Brazil’s ANVISA regulator and ANMAT agreed to harmonise their respective pharmacopoeias, or drug classification and listing systems. This too is a positive move, as ANVISA has emerged as one of the most proactive in the Latin American region in improving methodology and enforcement.